TY - JOUR. T1 - The ITMIG/IASLC thymic epithelial tumors staging project. T2 - A proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors. AU - Bhora, Faiz Y.. AU - Chen, David J.. AU - Detterbeck, Frank C.. AU - Asamura, Hisao. AU - Falkson, Conrad. AU - Filosso, Pier Luigi. AU - Giaccone, Giuseppe. AU - Huang, James. AU - Kim, Jhingook. AU - Kondo, Kazuya. AU - Lucchi, Marco. AU - Marino, Mirella. AU - Marom, Edith M.. AU - Nicholson, Andrew G.. AU - Okumura, Meinoshin. AU - Ruffini, Enrico. AU - Van Schil, Paul. AU - Goldstraw, Peter. AU - Rami-Porta, Ramón. AU - Ball, David. AU - Beer, David. AU - Beyruti, Ricardo. AU - Bolejack, Vanessa. AU - Chansky, Kari. AU - Crowley, John. AU - Eberhardt, Wilfried Ernst Erich. AU - Edwards, John. AU - Galateau-Sallé, Françoise. AU - Giroux, Dorothy. AU - Gleeson, Fergus. AU - Groome, Patti. AU - Kennedy, Catherine. AU - Kim, Young Tae. AU - Kingsbury, Laura. AU - Kondo, ...

TY - JOUR. T1 - Apoptosis in thymic epithelial tumors. AU - Park, Sung Hye. AU - Kim, Han Kyeom. AU - Kim, Hanseong. AU - Ro, Jae Y.. PY - 2002/1/1. Y1 - 2002/1/1. N2 - We studied Fas/FasL, Bcl-2, and M30 CytoDeath in five cases of normal thymus and 41 cases of thymic epithelial tumors (TETs). In normal thymus, Fas was expressed in all epithelial cells, but not in thymic lymphocytes; FasL was weakly expressed only in medullary epithelium and Hassals corpuscles. In TETs, Fas was expressed in all epithelial cells and lymphocytes, while FasL was differently expressed in epithelial cells of different subtypes of TETs, i.e., type A (2/2), AB (12/12), B1 (0/9), B1/B2 (0/3), B2 (0/1), B2/B3 (1/3), B3 (6/10) and C (1/1), but not in lymphocytes. Bcl2 protein was strongly expressed in medullary-derived lymphocytes of normal thymus and TETs, and weakly expressed only in medullary (spindle) epithelium of TETs. On M30 CytoDeath immunostaining, apoptotic indices were very low in all TETs (0-1.2). In ...

TY - JOUR. T1 - Prognosis of surgically treated thymic epithelial tumors. AU - Horinouchi, Hirohisa. AU - Asakura, Keisuke. AU - Kimura, Yoshishige. AU - Takeuchi, Ken. AU - Kawamura, Masafumi. AU - Watanabe, Masazumi. AU - Eguchi, Keisuke. AU - Kobayashi, Koichi. PY - 2006/11. Y1 - 2006/11. N2 - This study was performed to clarify the prognosis of patients with surgically treated thymic epithelial tumors. The records of 131 patients who underwent surgical treatment during 1985-2005 were retrospectively reviewed. Pathologic review was done according to the WHO classification of tumors of the thymus. Patients characteristics were: 76 male and 55 fimale; average age 53 (range 20-80) years; tumor stage was stage I in 42, stage II in 43, stage III in 23, stage IVa in 15, stage IVb in 1, and thymic carcinoma (squamous cell carcinoma) in 7 based on Masaokas staging. There were 7 cases of type A, 23 of type AB, 30 of type B1, 27 of type B2, 29 of type B3, and 15 of type C. Surgical procedures ...

To gain further insight into the biology of thymic tumors, we did a comprehensive molecular analysis of 45 resected thymic tumors. To our knowledge, this study represents one of the first and largest of its kind. Previous studies have focused on only a small number of tumors (29) and used only a limited number of analytic methods (29-31). Our analysis has three main new findings.. First, mutational analysis of genes encoding components of the EGFR signaling pathway led to the identification of RAS mutations in 3 (7%) of 45 thymic epithelial tumors. Previously, investigators have collectively assessed the status of only one RAS gene (i.e., KRAS) in 17 tumors (16, 32, 33) but did not identify any mutation. In our study, two RAS mutant tumors were thymomas (type A and B2) that are low grade, and the other tumor was a thymic carcinoma that is high grade. KRAS mutations predict for primary resistance to anti-EGFR directed therapies [i.e., gefitinib/erlotinib in lung cancer (34) and cetuximab in colon ...

TY - JOUR. T1 - Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis. AU - Roden, Anja. AU - Yi, Eunhee S.. AU - Jenkins, Sarah M.. AU - Edwards, Kelly K.. AU - Donovan, Janis L.. AU - Lewis, Jean E.. AU - Cassivi, Stephen D.. AU - Marks, Randolph Stuart. AU - Garces, Yolanda Isabel. AU - Aubry, Marie Christine. PY - 2015/3/30. Y1 - 2015/3/30. N2 - Data regarding the prognostic significance of the histopathologic classifications of thymic epithelial neoplasms are contradictory, perhaps reflecting issues in reproducibility. We studied the effect of reproducibility of 3 histopathologic classifications on prognosis and investigated the interobserver agreement on invasion and its effect on staging and prognosis. A total of 456 patients who underwent surgery for thymic epithelial neoplasm at Mayo Clinic Rochester (1942 to 2008) were staged (modified Masaoka, proposed Moran, proposed IASLC/ITMIG) and independently classified ...

TY - JOUR. T1 - Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 world health organization in patients treated with octreotide and prednisone. T2 - an eastern cooperative oncology group study. AU - Aisner, Seena C.. AU - Dahlberg, Suzanne. AU - Hameed, Meera R.. AU - Ettinger, David S.. AU - Schiller, Joan H.. AU - Johnson, David H.. AU - Aisner, Joseph. AU - Loehrer, Patrick J.. PY - 2010/6. Y1 - 2010/6. N2 - BACKGROUND:: Advanced or recurrent nonresectable thymic epithelial tumors show only a modest response to standard chemotherapy. A recent study using octreotide and prednisone in thymic tumors, Eastern Cooperative Oncology Group study E1C97, was conducted to verify the activity of octreotide for thymic tumors. The aim of this study was to determine whether epidermal growth factor receptor (EGFR) immunoreactivity correlated with outcomes and to identify new biologic markers for potential ...

TY - JOUR. T1 - Thymic tumor with adenoid cystic carcinomalike features. T2 - A clinicopathologic study of 4 cases. AU - Di Tommaso, Luca. AU - Kuhn, Elisabetta. AU - Kurrer, Michael. AU - Zettl, Andreas. AU - Marx, Alex. AU - Müller-Hermelink, Hans Konrad. AU - Roncalli, Massimo. AU - Rosai, Juan. PY - 2007/8. Y1 - 2007/8. N2 - Thymic carcinomas are rare malignant neoplasms which comprise several histologic subtypes. Adenoid cystic carcinoma (ACC) is included among these subtypes even if it has never been formally reported. We evaluated the clinical, radiologic, morphologic, immunohistochemical, and genetic features of 4 cases of thymic neoplasms with ACC-like features retrieved from the authors consult files. Most cases affected adult/elderly males (mean 68.5 y; range: 63 to 77 y; M:F ratio=3:1), and were asymptomatic. The clinical history (no evidence of ACC in other sites), radiologic findings (a mass in the thymic region), and morphologic features (residual thymic tissue at the periphery ...

title: Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution., doi: 10.1016/j.ejcts.2009.02.019, category: Article

Overview Masses in the anterior mediastinum include neoplasms (e.g., thymomas, lymphomas, thymic carcinomas, thymic carcinoids, thymolipomas, germ cell tumors, parathyroid adenomas) or nonneoplastic conditions (e.g., intrathoracic goiter, thymic cysts, lymphangiomas, aortic aneurysms).1,2 Thymomas are the most common tumor in the anterior mediastinum.1,3,4 Many mediastinal masses are benign, especially those occurring in asymptomatic patients; however, symptomatic patients often have malignant mediastinal lesions. These guidelines outline the evaluation, treatment, and management of thymomas and thymic carcinomas (see Thymic Masses, opposite column). The WHO histologic classification system can be used to distinguish among thymomas, thymic carcinomas, and thymic carcinoids.3 Lymphomas typically manifest as generalized disease but can also be primary anterior mediastinal lesions (i.e., nodular sclerosing Hodgkin disease and non-Hodgkins lymphomas [large B-cell lymphoma and lymphoblastic ...

Overview Masses in the anterior mediastinum include neoplasms (e.g., thymomas, lymphomas, thymic carcinomas, thymic carcinoids, thymolipomas, germ cell tumors, parathyroid adenomas) or nonneoplastic conditions (e.g., intrathoracic goiter, thymic cysts, lymphangiomas, aortic aneurysms).1,2 Thymomas are the most common tumor in the anterior mediastinum.1,3,4 Many mediastinal masses are benign, especially those occurring in asymptomatic patients; however, symptomatic patients often have malignant mediastinal lesions. These guidelines outline the evaluation, treatment, and management of thymomas and thymic carcinomas (see Thymic Masses, opposite column). The WHO histologic classification system can be used to distinguish among thymomas, thymic carcinomas, and thymic carcinoids.3 Lymphomas typically manifest as generalized disease but can also be primary anterior mediastinal lesions (i.e., nodular sclerosing Hodgkin disease and non-Hodgkins lymphomas [large B-cell lymphoma and lymphoblastic ...

Recent work with immunotherapy has shown promising results with treatment of several solid malignancies, and there are several reports of good systemic responses with the combination of immunotherapy and radiation therapy (RT), most notably in advanced melanoma. Given the rapid increase in the use of checkpoint blockade as well as anti-tumor vaccines, we review here the preclinical rationale and ongoing clinical work in combining immunotherapy with RT for small cell lung cancer (SCLC) and thymic tumors. While there are several reports of promising results with the combination of immunotherapy and conventional systemic treatment, we focus here on the ongoing clinical studies that combine immunotherapy with RT, and highlight the emerging data for this multimodality approach as well as key preclinical and clinical issues that remain to be addressed. With regards to SCLC, trials exploring to the combination of immunotherapy and RT are already ongoing, but clinical studies for this combination in thymoma are

TY - JOUR. T1 - The Integrated Genomic Landscape of Thymic Epithelial Tumors. AU - The Cancer Genome Atlas Network. AU - Radovich, Milan. AU - Pickering, Curtis R.. AU - Felau, Ina. AU - Ha, Gavin. AU - Zhang, Hailei. AU - Jo, Heejoon. AU - Hoadley, Katherine A.. AU - Anur, Pavana. AU - Zhang, Jiexin. AU - McLellan, Mike. AU - Bowlby, Reanne. AU - Matthew, Thomas. AU - Danilova, Ludmila. AU - Hegde, Apurva M.. AU - Kim, Jaegil. AU - Leiserson, Mark D.M.. AU - Sethi, Geetika. AU - Lu, Charles. AU - Ryan, Michael. AU - Su, Xiaoping. AU - Cherniack, Andrew D.. AU - Robertson, Gordon. AU - Akbani, Rehan. AU - Spellman, Paul. AU - Weinstein, John N.. AU - Hayes, D. Neil. AU - Raphael, Ben. AU - Lichtenberg, Tara. AU - Leraas, Kristen. AU - Zenklusen, Jean Claude. AU - Ally, Adrian. AU - Appelbaum, Elizabeth L.. AU - Auman, J. Todd. AU - Balasundaram, Miruna. AU - Balu, Saianand. AU - Behera, Madhusmita. AU - Beroukhim, Rameen. AU - Berrios, Mario. AU - Blandino, Giovanni. AU - Bodenheimer, Tom. AU - ...

Chemotherapy is the definitive treatment for inoperable or recurrent thymoma and thymic carcinoma. It can also be used to decrease the size of potentially operable tumors in order to increase the chances of successful surgery. Several chemotherapy drugs are active against thymic cancers. These include cisplatin, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, etoposide, pemetrexed, gemcitabine, capecitabine and ifosfamide. In general, a combination of chemotherapy drugs is used for treatment of newly diagnosed inoperable thymic cancers or for pre-surgical treatment of locally advanced disease. Recurrent thymic cancers are usually treated with a single drug, although combination chemotherapy can also be considered in select cases. Commonly used combinations for treatment of newly diagnosed advanced thymoma or thymic carcinoma include cisplatin with doxorubicin and cyclophosphamide (commonly referred to as the PAC or CAP regimen), cisplatin with etoposide, or carboplatin with paclitaxel. ...

Background: Thymomas and thymic carcinomas are rare malignancies and devising clinically effectivemolecular targeted therapies is a major clinical challenge. The aim of the study was to analyze BLC2 andvascular endothelial growth factor receptor (VEGFR) expression and KRAS and EGFR mutational status andto correlate them with the clinical characteristics of patients with thymomas and thymic carcinomas. Materialsand Methods: A total of 62 patients (mean age: 50.4±13.2 years) with thymomas and thymic carcinomas wereenrolled. The expression of BLC2 and VEGFR in tumor cells and normal tissues was evaluated by RT-PCR.The mutational status of the KRAS and EGFR genes was investigated by PCR with sequence specific primers.Results: The BLC2 and VEGFR expression levels did not differ significantly between tumor and normal tissues.Moreover, there were no clearly pathogenic mutations in KRAS or EGFR genes in any tumor. None of themolecular markers were significantly related to clinical outcomes. Conclusions:

Clinical trial for Recurrent Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Unresectable Thymic Carcinoma | Metastatic Thymic Carcinoma , Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced Recurrent or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

A single mutation in the transcription factor GTF2I may help differentiate fast-growing cancers of the thymus that require aggressive treatment from slow-growing ones that dont require extensive therapy, according to a study published in Nature Genetics.. Conducted by researchers from Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, and the NCI, the study involved thymic epithelial tumors (TET), which are subdivided into thymomas and thymic carcinomas; thymomas are further classified into types A, AB, B1, B2, and B3 based on histological features. All begin in the epithelial cells of the thymus, a lymphatic system organ where T cells mature. Together, they account for only 0.2% to 1.5% of all cancers.. In addition to being rare, there is an insufficient characterization of the genetic abnormalities in these tumors, says the studys senior investigator Guiseppe Giaccone, MD, PhD, associate director for clinical research at Georgetown. Having a GTF2I mutation as a marker ...

Thymic epithelial tumors (TET) are rare. Wingless and INT (WNT), NOTCH and sonic hedgehog pathway interactions between thymocytes and thymic stroma are important to thymus and T-cell development. We analyzed a thymoma tissue microarray (TMA) for glioma associated oncogene homolog 1 (GLI1), NOTCH1 and catenin (cadherin-associated protein, beta 1) (CTNNB1) expression as surrogate markers of sonic hedgehog, NOTCH and WNT pathway activity.GLI1, NOTCH1 and CTNNB1 expression were assayed in a tissue microarray of 68 TET and eight benign thymus by fluorescent immunohistochemistry (AQUA) as surrogates for activity of the sonic hedgehog, NOTCH and WNT pathways respectively.No difference in tumor GLI1 (mean 201 vs. 211, p=0.31), CTNNB1 (mean 222 vs. 306, p=0.66) or NOTCH1 expression (mean 317 vs. 325, p=0.82) was noted between thymic tumor and benign thymus.No evidence for preferential expression of GLI1, NOTCH1 or CTNNB1 was noted. High-throughput immunofluorescence using AQUA technology can help ...

A risk factor is something (such as a behaviour, substance or condition) that increases the risk of developing cancer. There are no known risk factors for thymic tumours, but there are some possible risk factors. Most cancers are the result of many risk factors, but sometimes thymic tumours develop

article{Mediastinum4558, author = {Kwon Joong Na and Samina Park and In Kyu Park and Young Tae Kim and Chang Hyun Kang}, title = {AB010. OA02.01: Comparison of factors affecting length of stay after surgery for thymic tumors: minimally invasive vs . open surgeries}, journal = {Mediastinum}, volume = {2}, number = {0}, year = {2018}, keywords = {}, abstract = {}, url = {http://med.amegroups.com/article/view/4558 ...

The doctor mentioned in the article, Patrick Loehrer, Alan actually contacted him a year ago and they DO correspond. He is the expert but unfortunately he sees mostly thymomas - there isnt too much thymic to see. SO his work and trials are geared to thymomas. This is the problem.. All of the oncologists we talk to know that the mix he uses is extremely toxic and it may be of some value in thymomas [hes seen more than any other dr.]. But the protocol is not proven for thymic cancers. They dont know if it works at all for thymic. Unfortunately. It is so toxic due to the combination they choose, that most patients cant finish the series due to extreme side affects and many of the others die at the end [Johns Hopkins did a study]. SO that is why the oncologists say until I absolutely need it, theyd like to wait. We are tending to agree. I dont want to end up like my mother where the treatment killed her. It almost happened with the radiation last year.. There has to be a better way.. He has ...

Insight Biotechnology supply high quality reagents for cell and molecular biology, specializing in antibodies for medical research.

Need for customized tissue samples?. If you need a more differentiated selection of samples, cannot find what you are looking for, or wish a consultation, please do not hesitate using our contact form or get in touch via phone or email. » [email protected] ...

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patients clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...

Affiliation：東京女子医科大学,医学部,教授, Research Field：Obstetrics and gynecology,Hygiene, Keywords：フリーラジカル,胎児脳神経障害,アロプリノール,NMDAレセプター,臍帯,モンテビオ単位,子宮筋弛緩剤,胎児(仔)呼吸様運動,パワー値,umbilical cord, # of Research Projects：5, # of Research Products：8

The objective of this study was to re-examine histologically and restage thymic epithelial tumours during a 25-year period and to correlate clinical and follow-up data. We utilized centralized registries in Iceland to establish a true nationwide incidence rate, previously unreported. A retrospective whole population study was carried out by including all patients diagnosed with a thymic epithelial tumour in Iceland between 1 January 1984 and 30 April 2010. Medical records were reviewed and presenting symptoms, diagnostic procedures and surgical outcome tabulated. The histology of all cases was reclassified according to the 2004 World Health Organization classification (A-TC). The Masaoka system was used for tumour staging. Median follow-up was 67 months. A total of 19 patients were identified, 11 men (58%) and 8 women, with mean age at presentation of 63 years (31-87 years). The age-standardized incidence rate (ASR) was 0.3 and 0.2/100 000/year for men and women, respectively. Types B2 (n = 5) ...

TY - JOUR. T1 - Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. AU - Lemma, Girum L.. AU - Lee, Ju Whei. AU - Aisner, Seena C.. AU - Langer, Corey J.. AU - Tester, William J.. AU - Johnson, David H.. AU - Loehrer, Patrick J.. PY - 2011/5/20. Y1 - 2011/5/20. N2 - Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response ...

The present study aimed to investigate the expression and association of the single-nucleotide polymorphism (SNP) -1637A/G in the promoter region of the T cell immunoglobulin domain and mucin domain protein-1 (Tim-1) gene in patients diagnosed with thymoma with or without myasthenia gravis (MG). The expression of Tim-1 was detected using the streptavidin peroxidase immunohistochemical staining method on tissues obtained from thymoma patients with (n=58) and without (n=62) MG. The Tim-1 gene -1637A/G polymorphism was detected using the single allele-specific primer polymerase chain reaction. The positive rate of Tim-1 expression in thymoma patients with MG was 62.1% (32/58), which was significantly higher compared with that in thymoma patients without MG (33.9%, 21/62) (P=0.002). The genotype frequencies of GG, GA and AA in the -1637A/G polymorphism were 0.7931, 0.2069 and 0, respectively, in thymoma patients with MG, and 0.6129, 0.3871 and 0, respectively, in thymoma patients without MG. A ...

pISSN 1738-1843 eISSN 2092-8920 © 2013 The Korean Society of Pathologists/The Korean Society for Cytopathology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Thymolipoma is a rare anterior mediastinal tumor composed of mature adipose tissue and benign thymic tissue, and is a benign neoplasm for which complete surgical excision is curative. Literature has reported that the thymic parenchyma of thymolipoma exceptionally contain myoid cells that are immunoreactive for desmin, muscle-specific actin and myoglobin. Herein, we describe a very rare case of thymolipoma with myoid cells. To the best of our knowledge, this is the sixth case of thymolipoma containing striated myoid cells in the English literature since 1972.

The present study retrospectively examined the diagnostic utility of adding positron emission tomography (PET) or magnetic resonance imaging (MRI) to computed tomography (CT) alone for preoperative diagnosis of anterior mediastinal tumors. A total of 104 consecutive patients who had undergone surgical resection of anterior mediastinal tumors were divided into two groups: Additional PET to another modality and no additional PET to another modality, and further subdivided into three groups: CT alone, additional MRI to CT and additional PET to CT. The sensitivity, specificity, and accuracy for diagnosing malignant tumors in each subgroup was calculated. Comparing the two groups, the diagnostic sensitivity was similar for additional PET (98.0%) and no additional PET (95.2%) groups; however, the specificity and accuracy for additional PET (75.0 and 92.2%, respectively) were significantly improved compared with no additional PET (31.6 and 65.0%, respectively). In the subgroup analysis, adding PET to ...

Thymoma and Thymic Carcinoma Treatment cost in India starts from USD . Find affordable packages, best specialists, hospitals and patient experiences for Thymoma and Thymic Carcinoma Treatment in India through Vaidam.

Thymoma and thymic carcinoma originate within the epithelial cells of the thymus, resulting in an anterior mediastinal mass. The term thymoma is customarily used to describe neoplasms that show no overt atypia of the epithelial component, whereas, a thymic epithelial tumor that exhibits clear-cut cytologic atypia and...

ABSTRACT. Background: We reported our experience with thymic carcinomas and review their clinical features, treatment strategies, and prognoses. Methods: From April 1998 to November 2012, 11 patients pathologically diagnosed with thymic carcinoma and treated in our hospital were investigated. Results: There were 7 men and 4 women, with a median age of 62 years (range, 35 - 72). According to the Masaoka staging system, 3 patients had stage II, 1 stage III disease, 3 stage IVa disease and 4 stage IVb disease. Ten patients had squamous cell carcinoma, whereas 1 had large cell neuroendocrine carcinoma (LCNEC). We performed surgery or multimodality therapy including surgery as the initial therapy for 8 patients. Of the non-surgical cases, 1 patient received chemoradiotherapy and survived for over 6 years without recurrence, whereas 2 received palliative care. Three of 4 patients who underwent complete resection survived without disease recurrence, whereas only 1 patient with LCNEC survived in the ...

Disease Overview Thymomas and thymic carcinomas are epithelial tumors of the thymus. The term, thymoma, is customarily used to describe neoplasms that show no overt atypia of the epithelial component. A thymic epithelial tumor that exhibits clear-cut cytologic atypia and histologic features no longer specific to the...

In 1999, the World Health Organization (WHO) Consensus Committee published a histologic classification of tumors of the thymus. In this scheme, thymomas are classified on the combined basis of the morphology of the neoplastic epithelial cells and the lymphocyte-to-epithelial cell ratio. This classification has resulted in six separate histologic subtypes of thymomas (types A, AB, B1, B2, B3, and C) (Table 7-1). An update on the WHO classification was published in 2004.27 It retained its classifications of A through B3 thymomas but relegated type C to a separate category of thymic carcinoma and acknowledged that certain types of thymoma do not fall into these categories. The applicability and clinical significance of the WHO histologic classification of thymomas is still being evaluated. It appears that most thymomas can be classified using the WHO criteria, although the clinical and prognostic relevance of this classification has not been conclusively determined. Most thymomas of types A and AB ...

Introduction: Thymic malignancies represent a wide range of clinical, histological and molecular entities, with considerable heterogeneity even among tumors of the same histotype. Thymomas are rare neoplasms arising from tissue elements of the thymus and developing in the anterior mediastinum, with an annual incidence of only 0.15 cases per 100, 000 person-years. They can be associated with a variety of systemic and autoimmune disorders, such as pure red cell aplasia, pancytopenia, hypogammaglobulinemia, collagen-vascular disease, and most commonly with myasthenia gravis. Surgical resection remains the cornerstone of therapy for early-stage disease, while in advanced or recurrent forms, a multimodality approach incorporating radiation and chemotherapy is required. Platinum with anthracycline-based chemotherapy is an optimal combination for advanced thymoma. Case Report: We hereby present an interesting case of thymoma which was detected on imaging for routine health check-up and was managed successfully

Background: Mediastinal masses are relatively uncommon lesions that sometimes pose an interesting diagnostic and therapeutic problem for the clinician. Thymomas are one of the common mediastinal neoplasms and exhibit a wide spectrum of morphologic features and an unrivalled frequency of other autoimmune diseases. The great morphologic variability and heterogeneity in thymomas has rendered their histological classification difficult and highly controversial. Methods: This retrospective and descriptive study on thymoma was done in the department of pathology, Kasturba Medical College Mangalore (Manipal University), India over a period of five years from January 2006 to June 2011. Histopathology sections taken were stained with routine Hematoxylin and Eosin stains in every case. Additional stains and immunohistochemistry were done as required. Results: Total number of mediastinal lesions studied was 66, with thymomas making up 15 cases. The age range of patients with thymomas was 22 to 65 years ...

Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM).|i| Case Description|/i|. We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy. Subsequently, refractory hypercalcemia persisted despite the administration of bisphosphonates and denosumab indicative of refractory hypercalcemia. Elevated 1,25-dihydroxyvitamin D was noted from the second admission with hypercalcemia responding to glucocorticoid administration. A subsequent PTHrP was also elevated, further supporting multiple mechanistic evolution of HCM. The different mechanisms of HCM are summarized with the role of tailoring therapies based on the particular

accuracy accurate addition adult adulthood advantages among anterior applications approved assessment assumed asymmetry audience averaging axial body capability channel characterization chemical china clinical clinicians cohort coil committee consents considerably consultants decomposition density deposition detected differentiate differentiating differentiation diffusion disease distinguishing divided dual effectiveness epithelial equal estimation ethics evaluate evaluation examination examinations experienced final forty fourth fraction freehand gang gives gland gradient help helpful hence hospital hyperplasia ideal improvements index informed instruments intensity iterative least lesion lesions limitations liver long lymphoid lymphoma lymphomas medical military modality oncology overlapping participants particular parts patient people placed plots post practice preferable previously protocols proton providing qualitative quantitative quantization radiologist radiology rebound recent recently ...

The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma pre

Myasthenia gravis is the best known autoimmune disease associated with thymomas, but other conditions can be found in patients with thymic tumors, including some that affect the central nervous system (CNS). We have become particularly interested in patients who have acquired neuromyotonia, the rare Morvan disease, or limbic encephalitis. Neuromyotonia mainly involves the peripheral nerves, Morvan disease affects both the peripheral nervous system and CNS, and limbic encephalitis is specific to the CNS. Many of these patients have voltage-gated potassium channel autoantibodies. All three conditions can be associated with thymomas and may respond to surgical removal of the underlying tumor together with immunotherapies and symptomatic treatments. Herein, we review the results of our recent studies that show that voltage-gated potassium channel autoantibodies are not principally directed against the potassium channels themselves but in some patients are directed against a protein that is complexed with

Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 world health organization in patients treated with octreotide and prednisone: an eastern cooperative oncology group study Academic Article ...

Thymoma and thymic carcinoma are diseases in which malignant (cancer) cells form on the outside surface of the thymus. The thymus, a small organ that lies in the upper chest under the breastbone, is part of the lymph system. It makes white blood cells, called lymphocytes, that protect the body against infections...

Learn about thymoma and thymic carcinoma, two cancers affecting the thymus. Its a small gland that makes white blood cells that fight infection.

IUCRO-0031; Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma study is currently recruiting healthy volunteers at Indiana CTSI, IN

thymomas WP WebPathology PO Definition: Thymoma is the most frequent tumor arising in human thymus (thymic tumors). Thymoma is a tumor (...)

The main characteristics of the patients included in this study are shown in Table 1. Tumor histology has been classified according to the World Health Organization (WHO) proposal.16 The majority of the patients received thymectomy and showed an inversion of the CD4+/CD8+ ratio. Five patients were suffering from severe immunodeficiency syndrome characterized by recurrent infections of the lower respiratory tract. Flow cytometry analyses were performed at monthly intervals in the last 6 months, showing a stable reduction of mature CD19+ peripheral cells (unique patient numbers [UPNs] 091, 157, 051, 009, 147). A marked hypogammaglobulinemia had been detected in 4 of the 5 patients, whereas 1 of them (UPN 091) had normal immunoglobulin (Ig) serum levels. On the bases of clinical signs and B lymphopenia, we classified these patients as suffering from Good syndrome. We included in the study also 2 thymoma patients with normal Ig serum levels, normal B-cell counts, and no signs of severe recurrent ...

Thymomas are usually benign tumors, but they can also be malignant. Thymomas are rare tumors often associated with an autoimmune disease, the most common of which is myasthenia gravis.

Thymomas comprise about 1% of all mediastinal tumours and are rare in children. Typically, these tumours are aggressive, with a poor outcome. The current treatment of invasive thymoma is often multidisciplinary. We report a 16-year-old boy with invasive thymoma who was successfully treated with systemic chemotherapy, surgical resection and irradiation. The patient has been in continuous remission for 6 years without radiographic evidence of tumour recurrence.. ...

/PRNewswire/ -- Castle Biosciences Inc. today announced data from a study of a genetic test demonstrating high accuracy in differentiating thymomas from thymic...

Find the best thymomas doctors in Mumbai. Get guidance from medical experts to select thymomas specialist in Mumbai from trusted hospitals - credihealth.com

Treatment protocols for thymoma are provided below, including treatment by Masaoka clinical stage, chemotherapy regimens, recommendations for recurrent or metastatic disease, and radiotherapy regimens. Treatment recommendations based on Masaoka clinical stage Stage I: Complete surgical excision is the treatment of choice for nonmetastatic t...

Factors influencing the length of stay after mediastinal tumor resection in the setting of an enhanced recovery after surgery (ERAS)-TUBELESS protocol

Select Patients / Caregivers / Public or Researchers / Professionals to filter your results. To further refine your search, toggle appropriate sections on or off. ...

Learn about mediastinal tumors and how our team can best help you by using novel approaches to biopsies and minimally invasive, video-assisted procedures.

Mediastinal Tumors - RWJBarnabas Health is a leading provider of compassionate, quality, & cost-efficient medical care services in the state of New Jersey.

Diarrhoea is a common symptom for which the aetiology will be straightforward in many cases. However, when a common aetiology is not found, the wide variety of other options can feel like finding a needle in a haystack. In this case report, we describe a patient who was referred to our centre with therapy-resistant, secretory diarrhoea, which was the presenting symptom of Goods syndrome, a rare form of adult-onset immunodeficiency associated with thymoma. The conclusions from this case report give direction for finding the needle and contribute to a focused approach to patients who present with therapyresistant diarrhoea ...

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...

This video demonstrates how safe and fast a robotic excision of thymic carcinoma along with an extended thymectomy and the excision of affected pericardium can be, compared to a standard median... More ...

Patient ID: 703/19, Format: FFPE, Type: Tumor, Sample Vol mL: , Gender: Male, Age: 32, Race: Caucasian, Ethnicity: Slavic, Organ: Mediastinum, Clinical Diagnosis: Mediastinal carcinoma, Pathological Diagnosis: Malignant epithelioid tumor (probably Thymoma B3 type), need IHC, T, N, M = T3, Nx, Mx, Grade: G1, Stage: III, Lymph Node Metastases: no, Distant Metastasis: no, Tumour = 80%, Necrosis = 0%, Hours & Minutes before fixation in formalin = 015, HIV = Neg, HEP B = Neg, HEP C = Neg, Patients Height: cm, Patients Weight: kg, Current Medications: , Smoking: , Smoking Type: , Smoking Pack/Day = , Smoking Duration Years = , Smoking When Quit: , Alcohol: , Drug Use: , Hormonal Therapy: no, Prev Chemotherapy: no, Prev Radiation: no, Current Procedure/Operation: resection, Date of Procurement: 43556, Country of Collection: Georgia

Light micrograph of normal human thymus. The thymus is divided into lobules separated by septa of connective tissue (white spaces) which may contain blood vessels (as at right, stained red and very dark purple). Each lobule has a cortex (granular masses, densley packed, picture periphery) of lymphocytes, and a medulla (centre) of lymphocytes and stellate epitherial cells. The circular pink structures within the medulla (one prominent) are concentrically arranged epitherial cells of uncertain function. Magnificaton: x20 at 35mm size. - Stock Image P264/0004

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited ...

Infectious Disease Advisor is used by specialists and other medical professionals to help understand and treat infectious diseases. Latest news, research and treatment articles.

Thymoma is a neoplasm of thymic epithelial cells. This definition excludes other tumors that may affect the thymus, such as lymphoma and germ cell tumors.

Dr. Michael Thompson answered: Thymus: A thymoma is a tumor of the thymus, a gland in the anterior chest. This gland is present as ...

Diagnosis of thymoma (costs for program #273927) ✔ University Hospital Ulm ✔ Department of General and Abdominal Surgery ✔ BookingHealth.com

article{{Mediastinum}{4556}, author = {Casini, B., Sarti, D., Gallo, E., Alessandrini, G., Cecere, F., Pescarmona, E., Facciolo, F., Marino, M.}, title = {AB008. OA01.08: Thymic carcinoma: preliminary data of next generation sequencing analysis}, journal = {Mediastinum}, volume = {2}, number = {0}, year = {2018}, url = {http://med.amegroups.com/article/view/4556 ...

Csh1 245 -3.31E+00 Melk 246 -3.30E+00 1459742_at 247 -3.30E+00 Nmnat3 248 -3.30E+00 A930015G24Rik 249 -3.29E+00 2810417H13Rik 250 -3.29E+00 Mrgprb1 251 -3.29E+00 1700061G19Rik 252 -3.29E+00 1459554_at 253 -3.28E+00 14378G7_at 254 -3.27E+00 Ceacam13 255 -3.27E+00 A130019P10Rik 256 -3.27E+00 Aqp11 257 -3.27E+00 2310047C04Rik 258 -3.27E+00 Dpp4 259 -3.27E+00 Otud1 260 -3.27E+00 1442468_at 261 -3.26E+00 B230101F01Rik 262 -3.26E+00 Tal2 263 -3.26E+00 Cplx1 264 -3.26E+00 Slc25a27 265 -3.26E+00 Spsb4 266 -3.25E+00 Mtm1 267 -3.25E+00 Bambi-ps1 268 -3.25E+00 1432510_ai 269 -3.25E+00 Pcmtd2 270 -3.25E+00 Clec2h 271 -3.24E+00 4930535E21Rik 272 -3.24E+00 1457234_at 273 -3.24E+00 Gm172 274 -3.23E+00 Gm996 275 -3.22E+00 E130014H08Rik 276 -3.22E+00 H2afy2 277 -3.22E+00 Defb3 278 -3.21E+00 Rbbp8 279 -3.20E+00 Dnase1l2 280 -3.19E+00 Sesn1 281 -3.19E+00 Accn3 282 -3.18E+00 4921537P18Rik 283 -3.18E+00 Hsd17b13 284 -3.18E+00 1810044A24Rik 285 -3.18E+00 Gas5 286 -3.18E+00 Flcn 287 -3.17E+00 Igh-4///Igh-6///Igh-V 288 ...

HerbsPro offers best RAW THYMUS Tb 60 by Ultra Glandulars that are produced according to manufacturing standards set by regulators at everyday low prices. Shop RAW THYMUS Tb 60 by Ultra Glandulars Online at HerbsPro.